Company Overview and News
KUALA LUMPUR (Oct 8): Construction counters this morning reacted negatively to news of the government's decision to retender MRT2's underground work, after terminating MMC-Gamuda KVMRT Sdn Bhd as the contractor.
5226 5253 5263 7078
Construction sector Maintain neutral: The outlook for the construction sector remains challenging as the federal government is reviewing ongoing infrastructure projects to reduce costs by 20%-33%. Projects that could be affected include the Klang Valley mass rapid transit Line 2 (MRT2) and light rail transit Line 3 (LRT3), Pan Borneo Highway (PBH) and Gemas-Johor Baru Electrified Double Tracking (EDT).
2852 9261 3204 5226 6238 5924 5263 5054 9679 5085 7078
KUALA LUMPUR (Oct 5): The FBM KLCI fell 0.38% at mid-morning today, tracking fragile regional markets.
UPBMF 7113 TPGVF BATS 4162 2291 5202 2089 9334 6033 9113 4634 TGLVY 5139 PNADF 5226 3301 NDAQ 0900 6888 5819 AXXTF 1902 PNAGF
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at mid-morning today on sustained weaker sentiment at the domestic market.
7083 5183 5172 PECGF BATS 4162 5014 5199 4634 KLKBY 2445 5226 4456 5347 3026 0026 TNABY MYPRY 2836 TNABF HIPEF
KUALA LUMPUR (Sept 6): Gabungan AQRS Bhd shares rose as much as 8 sen or 7% to RM1.18 so far today, after shareholders approved yesterday, the builder and property developer's proposed bonus issue of 123.65 million new warrants. The bonus issue will be undertaken on the basis of one warrant for every four existing shares held.
KUALA LUMPUR: Shares of Gabungan AQRS Bhd rose as much as 6.3% in early trade today, as the company sees brighter prospects for financial years ending Dec 31, 2019 (FY19) to FY21.
KUALA LUMPUR (July 5): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 6) may include: 7-Eleven Malaysia Holdings Bhd, Affin Bank Bhd, Gabungan AQRS Bhd, Hengyuan Refining Co Bhd, XOX Bhd, Nylex (Malaysia) Bhd, Ancom Bhd, Utusan Melayu (Malaysia) Bhd, Globaltec Formation Bhd, Censof Holdings Bhd and Dagang NeXchange Bhd (DNeX).
5226 5754 4456 PSKXF 5220 PHSXY PSE BCOR 5195
KOTA DAMANSARA (Sept 5): Gabungan AQRS Bhd expects better performance for financial years ending Dec 31, 2019 (FY19) to FY21, buoyed by its construction, property development and precast component manufacturing businesses.
REVIEW: Major developments cropped up over the past week on several fronts. On the domestic scene, the cancellation of the East Coast Rail Link (ECRL) project put an end to a potential turnaround in parts of the construction sector.
5226 BSMAF 1818
KUALA LUMPUR, Aug 22 ― The Malaysian workers in the East Coast Link Railway (ECRL) workers in Pahang are in a quandary after the prime minister confirmed the cancellation of the project in Beijing yesterday.
5226 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...